Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 9:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 98 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Venous Thromboembolism (VTE) Clear all
Withdrawn No phase listed Observational Accepts healthy volunteers

Systematic Review and Meta-Analysis of Venous Thromboembolism (VTE) Risk Assessment in Hospitalized Medical Patients

NCT01446510
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Application of VTE Risk Assessment
Other
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Apr 19, 2012 · Synced Oct 2, 2026, 9:12 PM EDT
Recruiting Phase 3 Interventional

REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants

NCT07213778
View directory record Official record
Conditions
Symptomatic Venous Thromboembolism (VTE)
Interventions
REGN7508, Acetylsalicylic Acid (ASA), Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
36
States / cities
La Mesa, California • Rancho Mirage, California • Riverside, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 2, 2026, 9:12 PM EDT
Completed No phase listed Observational

Risk Factors for Venous Thromboembolism in the Community

NCT00011180
View directory record Official record
Conditions
Cardiovascular Diseases, Thromboembolism
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
Not listed
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 6, 2012 · Synced Oct 2, 2026, 9:12 PM EDT
Terminated Not applicable Interventional Results available

Angel® Catheter Early Feasibility Clinical Study

NCT01847196
View directory record Official record
Conditions
Pulmonary Embolism, Deep Vein Thrombosis, Venous Thromboembolism
Interventions
Angel® Catheter
Device
Lead sponsor
BiO2 Medical
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
Jackson, Mississippi • Portland, Oregon • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2015 · Synced Oct 2, 2026, 9:12 PM EDT
Completed Not applicable Interventional Results available

Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer

NCT02744092
View directory record Official record
Conditions
Cancer, Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Blood Clot
Interventions
Rivaroxaban, Apixaban, Edoxaban, Dabigatran, Warfarin, Dalteparin, Enoxaparin, Fondaparinux
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older
Enrollment
811 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
151
States / cities
Chula Vista, California • Fremont, California • Fresno, California + 104 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Oct 2, 2026, 9:12 PM EDT
Completed Phase 3 Interventional Results available

Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term Prevention of Recurrent Symptomatic VTE

NCT00558259
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
dabigatran etexilate 150 mg twice daily (BID), matching placebo twice daily (BID)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
21
States / cities
Birmingham, Alabama • Huntsville, Alabama • Laguna Hills, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2014 · Synced Oct 2, 2026, 9:12 PM EDT
Completed Phase 3 Interventional Results available

Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty

NCT00657150
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Enoxaparin, Dabigatran etexilate
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
2,055 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
10
States / cities
La Jolla, California • Aurora, Colorado • Englewood, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2014 · Synced Oct 2, 2026, 9:12 PM EDT
Terminated Early Phase 1 Interventional Results available

Statin Use in Patients With Acute VTE

NCT02331095
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Atorvastatin, Anticoagulation Therapy
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 2, 2026, 9:12 PM EDT
Recruiting Phase 3 Interventional

The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer

NCT06861088
View directory record Official record
Conditions
Venous Thromboembolism, Metastatic Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma
Interventions
Kinisoquin™, Placebo
Drug
Lead sponsor
Quercis Pharma AG
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Ventura, California • Miami Lakes, Florida • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 2, 2026, 9:12 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism

NCT00291330
View directory record Official record
Conditions
Thromboembolism
Interventions
dabigatran etexilate 150 mg, warfarin (INR 2-3)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
2,564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
23
States / cities
Mobile, Alabama • Hartford, Connecticut • Clearwater, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2014 · Synced Oct 2, 2026, 9:12 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants

NCT02555878
View directory record Official record
Conditions
Neoplasms
Interventions
Rivaroxaban, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
841 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
70
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 67 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Oct 2, 2026, 9:12 PM EDT
Completed Phase 3 Interventional Results available

Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients

NCT00571649
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin, Rivaroxaban placebo, Enoxaparin placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
40 Years and older
Enrollment
8,101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
121
States / cities
Birmingham, Alabama • Dothan, Alabama • Geneva, Alabama + 107 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2016 · Synced Oct 2, 2026, 9:12 PM EDT
Completed Phase 3 Interventional Results available

Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement

NCT00152971
View directory record Official record
Conditions
Arthroplasty, Replacement, Knee, Thromboembolism
Interventions
Dabigatran Dose 1 - day 2 to completion, Dabigatran Dose 1 - day 1, Dabigatran Dose 2 - day 2 to completion, Dabigatran Dose 2 - day 1, Enoxaparin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
2,615 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
59
States / cities
Birmingham, Alabama • Northport, Alabama • Tucson, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated May 5, 2014 · Synced Oct 2, 2026, 9:12 PM EDT
Completed Phase 2 Interventional Results available

Odiparcil For The Prevention Of Venous Thromboembolism

NCT00244725
View directory record Official record
Conditions
Deep Vein Thrombosis, Fibrillation, Atrial, Venous Thromboembolism, Pulmonary Embolism
Interventions
Odiparcil, Warfarin, Coumadin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
35 Years and older
Enrollment
961 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
46
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated May 2, 2017 · Synced Oct 2, 2026, 9:12 PM EDT
Recruiting Not applicable Interventional

Computerized Decision Support for Prevention of VTE in Hospitalized Medical Patients Across the Continuum of Care (DC-eALERT)

NCT03728166
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Electronic alert
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 2, 2026, 9:12 PM EDT
Recruiting Phase 2 Interventional

Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For VTE Following Total Joint Arthroplasty

NCT04295486
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Aspirin
Drug
Lead sponsor
University of Miami
Other
Eligibility
19 Years and older
Enrollment
5,478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 2, 2026, 9:12 PM EDT
Completed Not applicable Interventional Results available

Education Bundle to Decrease Patient Refusal of VTE Prophylaxis

NCT02402881
View directory record Official record
Conditions
Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
Interventions
Patient-centered education bundle
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
19,652 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 6, 2020 · Synced Oct 2, 2026, 9:12 PM EDT
Completed Phase 1 Interventional

Fondaparinux (Arixtra) With Chemotherapy for Advanced Non-Small Cell Lung Cancer

NCT00476216
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Venous Thromboembolism
Interventions
Combination of Arixtra with chemotherapy
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 79 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 5, 2014 · Synced Oct 2, 2026, 9:12 PM EDT
Completed Phase 3 Interventional

Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Elective Knee Replacement Surgery

NCT00718224
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Semuloparin sodium, Enoxaparin, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
1,150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Oct 2, 2026, 9:12 PM EDT
Recruiting Phase 3 Interventional

DOAC - Dosing Options in AntiCoagulation Prophylaxis

NCT07005024
View directory record Official record
Conditions
Cancer, VTE (Venous Thromboembolism)
Interventions
Apixaban 2.5 mg twice daily, Apixaban 5 mg once daily, No anticoagulation
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
996 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 2, 2026, 9:12 PM EDT
Terminated Phase 2 Interventional

Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer

NCT00981903
View directory record Official record
Conditions
Venous Thromboembolism, Cancer
Interventions
Tinzaparin sodium
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Oct 2, 2026, 9:12 PM EDT
Recruiting Not applicable Interventional

AI-driven Clinical Decision Support to Reduce Hospital-Acquired Venous Thromboembolism: Study Protocol for the VTE-AI Randomized Trial.

NCT06939803
View directory record Official record
Conditions
Venothromboembolism
Interventions
Risk model-driven CDS
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Not listed
Enrollment
2,236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 2, 2026, 9:12 PM EDT
Recruiting Phase 3 Interventional

Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers

NCT07493304
View directory record Official record
Conditions
Venous Thromboembolism (VTE)
Interventions
REGN7508, Apixaban
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
3
States / cities
Hialeah, Florida • New York, New York • El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 2, 2026, 9:12 PM EDT
Completed Phase 4 Interventional

Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy

NCT01828697
View directory record Official record
Conditions
Deep Venous Thrombosis, Pulmonary Embolism
Interventions
Low dose nadroparin, Intermediate dose nadroparin, Low dose enoxaparin, Intermediate dose enoxaparin, Low dose dalteparin, Intermediate dose dalteparin, Fixed low dose tinzaparin, Intermediate dose tinzaparin
Drug
Lead sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
1,110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Oct 2, 2026, 9:12 PM EDT